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BAY 11-7082 (BAY) is an inhibitor of κB kinase (IKK) that has pharmacological activities that include anticancer, neuroprotective,
and anti-inﬂammatory eﬀects. In this study, BAY-pharmacological target pathways were further characterized to determine
how this compound simultaneously suppresses various responses. Primary and cancerous (RAW264.7 cells) macrophages were
activated by lipopolysaccharide, a ligand of toll-like receptor 4. As reported previously, BAY strongly suppressed the production
of nitric oxide, prostaglandin E2,a n dt u m o rn e c r o s i sf a c t o r - α and reduced the translocation of p65, major subunit of nuclear
factor-κB, and its upstream signaling events such as phosphorylation of IκBα, IKK, and Akt. In addition, BAY also suppressed
the translocation and activation of activator protein-1, interferon regulatory factor-3, and signal transducer and activator of
transcription-1 by inhibiting the phosphorylation or activation of extracellular signal-related kinase, p38, TANK-binding protein,
and Janus kinase-2. These data strongly suggest that BAY is an inhibitor with multiple targets and could serve as a lead compound
in developing strong anti-inﬂammatory drugs with multiple targets in inﬂammatory responses.
1.Introduction
Inﬂammatory signals activate inﬂammatory cells such as
blood vessel epithelial cells, macrophages, neutrophils, mast
cells, and lymphocytes to produce inﬂammatory mediators
These include cytokines such as interleukin (IL)-1, IL-6, and
tumor necrosis factor (TNF)-α; chemokines; toxic molecules
including nitric oxide (NO); lipidic mediators including
prostaglandin E2 (PGE2)[ 1, 2]. For these events, new tran-
scriptional and translational processes are required for sig-
naling cascades that are generated by the interaction between
a receptor (e.g., the toll-like receptor 4 [TLR4]) and a ligand
lipopolysaccharide(LPS)[3,4].Largenumbersofinﬂamma-
tory signaling enzymes such as nonreceptor protein tyrosine
kinases (e.g., Src, Syk, and Janus kinase [JAK]-2), serine-
threonine protein kinases (e.g., phosphoinositide 3-kinase
[PI3K], phosphoinositide-dependent kinase 1 [PDK1], Akt
[proteinkinaseB],andinhibitorofκBα[IκBα]kinase[IKK])
activate transcription factors such as nuclear factor (NF)-κB
and activator protein (AP)-1 [5, 6]. In response, numerous
inﬂammatory genes are expressed such as pro-TNF-α for
TNF-α secretion, inducible NO synthase (iNOS) for NO
release, and cyclooxygenase (COX)-2 for PGE2 production
[7–10].
BAY11-7082 (BAY, Figure 1(a)) is a representative IKK
inhibitor. Although IKK/NF-κB is important biochemi-
cal factor, the pharmacological activities of BAY such as
inhibition of inﬂammatory cytokines [11], induction of
heme oxygenase-1 [12], suppression of ICAM-1 expression
[13], reduction of ATPase activity of NLRP3 inﬂammasome
[14], and increase in neutrophil apoptosis [15]s t r o n g l y
indicate that it is not a selective inhibitor of only IKK.
Therefore, in this study, we explored its inhibitory potency
for inﬂammatory signals leading to the production of NO,
PGE2,a n dT N F - α under LPS-activated conditions, using
primary and cancerous (RAW264.7 cells) macrophages.2 Mediators of Inﬂammation
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Figure 1: Eﬀect of BAY (BAY 11-7082) on the production of NO, TNF-α, and PGE2 in RAW264.7 and peritoneal macrophages, and cell
viability. (a) Chemical structure of BAY. (b, c left panel, and d) Levels of NO determined by the Griess assay, TNF-α by ELISA, and PGE2 by
EIA from culture supernatants of RAW264.7 cell (b and d) and peritoneal macrophages (c) treated with BAY (0 to 15μM) in the presence
or absence of LPS (1μg/mL) for 6h (TNF-α) or 24h (NO and PGE2). (b and c right panel) Viability of RAW264.7 cells treated with BAY by
MTT assays. ∗P<0.05 and ∗∗P<0.01 compared to the control.Mediators of Inﬂammation 3
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Figure 2: Continued.4 Mediators of Inﬂammation
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Figure 2: Eﬀect of BAY on transcriptional activation of NF-κB. (a left panel, b, and g) Translocated or phosphorylated levels of NF-κB
subunitsfromnucleus(a)orwholelysates(b)ofRAW264.7cells(a,b,andgleftpanel)orperitonealmacrophages(grightpanel)treatedwith
BAY (15μM) in the presence or absence of LPS (1μg/mL) for indicated times, evaluated by immunoblotting. (c left panel to f) HEK293 cells
cotransfected with NF-κB-Luc construct (1μg/mL) and β-gal (transfection control) were treated with BAY (0 to 20μM) in the presence or
absence of PMA (100nM) or by cotransfection with NF-κB activation inducers (MyD88, TRIF, and TBK1). Luciferase activity was measured
using a luminometer. (a right panel and c right panel) Viability of RAW264.7 (a right panel) and HEK293 (c right panel) cells treated with
BAY (0 to 20 or 30μM) for 2 or 24h was examined by MTT assays. ∗P<0.05 and ∗∗P<0.01 compared to the control.
2.MaterialsandMethods
2.1. Materials. BAY 11-7082, or (E)-3-(4-methylphenylsul-
fonyl)-2-propenenitrile; lipopolysaccharide (LPS; Escheri-
chia coli 0111:B4); and 3-4,5-(dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) were from Sigma
ChemicalCo.(St.Louis,MO,USA).LY294002,wortmannin,
U0126 (U0), SB203580 (SB), SP600125 (SP), and PP2 were
from Calbiochem (La Jolla, CA, USA). Luciferase constructs
containing promoters sensitive to NF-κB, CREB, and AP-1
were gifts from Profs. Hae Young Chung (Pusan National
University, Pusan, Korea) and Man Hee Rhee (Kyungpook
National University, Daegu, Korea). Enzyme immunoassay
(EIA)kitsandenzyme-linkedimmunosorbentassay(ELISA)
kits for determining PGE2 and TNF-α were from Amersham
(Little Chalfont, Buckinghamshire, UK). Fetal bovine serum
and RPMI1640 were from Gibco (Grand Island, NY, USA).
The murine macrophage cell line RAW264.7 and the human
embryonic kidney cell line HEK293 were from the ATCC
(Rockville, MD, USA). All other chemicals were of analytical
grade and from Sigma. Phosphospeciﬁc or total antibodies
to p65, p50, Src, Syk, PDK1, p85, Akt, IκBα, p38, ERK, JNK,
laminA/C,andβ actinwerefromcellsignaling(Beverly,MA,
USA).
2.2. Mice. Six-week-old male C57BL/6 and ICR mice were
from DAEHAN BIOLINK (Chungbuk, Korea). Mice were
given food pellets (Samyang, Daejeon, Korea) and water
ad libitum under a 12-h light/dark cycle. Studies were
performed in accordance with guidelines established by the
Kangwon National University Institutional Animal Care and
Use Committee.
2.3. Preparation of Peritoneal Macrophages. Peritoneal exu-
dateswereobtainedfrommaleC57BL/6mice(7-8weeksold,
17–21g) by lavaging 4 days after intraperitoneal injection of
1mL of sterile 4% thioglycollate broth (Difco Laboratories,
Detroit, MI), as reported previously [16]. After washing
with RPMI 1640 medium containing 2% fetal bovine serum
(FBS),peritonealmacrophages(1×106 cells/mL)wereplated
in 100mm tissue culture dishes for 4h at 37◦Ci na5 %C O 2-
humidiﬁed atmosphere.
2.4.CellCulture. RAW264.7andHEK293 cellswerecultured
in DMEM or RPMI1640 medium supplemented with 10%
heat-inactivated FBS (Gibco, Grand Island, NY, USA), glu-
tamine,andantibiotics(penicillinandstreptomycin)at37◦C
u n d e r5 %C O 2. Cells were detached with a cell scraper. At
the cell density used for the experiments (2 × 106 cells/mL),Mediators of Inﬂammation 5
the proportion of dead cells was less than 1% as measured by
trypan blue dye exclusion.
2.5. Determination of NO, PGE2,a n dT N F - α. After preincu-
bationofRAW264.7cells(1×106 cells/mL)orbonemarrow-
derived macrophages (2 × 106 cells/mL) for 18h, cells were
pretreated with BAY (0 to 15μM) for 30min and further
incubated with LPS (1μg/mL) for 6 (TNF-α)o r2 4( N Oa n d
PGE2)h .L e v e l so fN O ,P G E 2,a n dT N F - α were determined
with Griess reagent and ELISA kits as described previously
[17, 18].
2.6. Cell Viability Test. After preincubation of RAW264.7
or HEK293 cells (2.5 × 106 cells/mL) for 18h, BAY (0 to
15 or 30μM) was added to the cells and incubated for 2
or 24h. The cytotoxic eﬀe c to fB A Yw a se v a l u a t e db ya
conventional MTT assay, as reported previously [19, 20].
At 1 or 3h before culture termination, 10μLM T Ts o l u t i o n
(10mg/mL in phosphate-buﬀered saline, pH 7.4) was added
to each well, and the cells were continuously cultured until
termination of the experiment. Incubation was halted by
the addition of 15% sodium dodecyl sulfate (SDS) into
each well, solubilizing the formazan [21]. Absorbance at
570nm (OD570–630) was measured using a SpectraMax 250
microplate reader.
2.7. Preparation of Cell Lysates and Nuclear Fraction, and
Immunoblotting. RAW264.7 cells (5 × 106 cells/mL) were
washed three times in cold PBS with 1mM sodium ortho-
vanadate and lysed by a sonicator in lysis buﬀer (20mM tris-
HCl, pH 7.4, 2mM EDTA, 2mM ethyleneglycotetraacetic
acid, 50mM β-glycerophosphate, 1mM sodium orthovana-
date, 1mM dithiothreitol, 1% Triton X-100, 10% glycerol,
10μg/mL aprotinin, 10μg/mL pepstatin, 1mM benzimide,
and 2mM PMSF) for 30min with rotation at 4◦C. Lysates
wereclariﬁedbycentrifugationat16,000xgfor10minat4◦C
a n ds t o r e da t−20◦C until needed.
Nuclear lysates were prepared in a three-step procedure
[22]. After treatment, cells were collected with a rubber
policeman, washed with PBS, and lysed in 500μLl y s i s
buﬀer containing 50mM KCl, 0.5% Nonidet P-40, 25mM
HEPES (pH 7.8), 1mM phenylmethylsulfonyl ﬂuoride,
10μg/mL leupeptin, 20μg/mL aprotinin, and 100μM1 , 4 -
dithiothreitol (DTT) on ice for 4min. Cell lysates were cen-
trifuged at 19,326xg for 1min in a microcentrifuge. In the
second step, the nuclear fraction pellet was washed once in
washing buﬀer (lysis buﬀer without Nonidet P-40). In the
ﬁnal step, nuclei were treated with an extraction buﬀer of
lysis buﬀer with 500mM KCl and 10% glycerol. The nuclei/
extraction buﬀer mixture was frozen at −80◦C, thawed on
ice and centrifuged at 19,326xg for 5min. The supernatant
was collected as a nuclear extract. Soluble cell lysates were
immunoblotted and protein levels determined as previously
reported [23].
2.8. Luciferase Reporter Gene Activity Assay. HEK293 cells
(1×106 cells/mL) were transfected with 1μg of plasmid con-
tainingNF-κB-Luc,IFN-β-promoter-Luc,CREB-Luc,orAP-
1 - L u ca sw e l la sβ-galactosidase using the polyethylenimine
Table 1: Real-time PCR primers.
Name Sequence (5  to 3 )
iNOS F GGA GCC TTT AGA CCT CAA CAG A
R TGA ACG AGG AGG GTG GTG
COX-2 F CACTACATCCTGACCCACTT
R ATGCTCCTGCTTGAGTATGT
GAPDH F CAA TGA ATA CGG CTA CAG CAA C
R AGG GAG ATG CTC AGT GTT GG
(PEI) method in a 12-well plate according to a previous
report[24].Cellswereused48haftertransfection.Luciferase
assays were performed using the Luciferase Assay System
(Promega) as reported previously [25].
2.9. mRNA Analysis by SemiQuantitative Reverse Transcrip-
tase- and Real-Time Polymerase Chain Reactions. To deter-
mine cytokine mRNA expression levels, total RNA was iso-
lated from LPS-treated RAW264.7 cells with TRIzol Reagent
(Gibco), according to the manufacturer’s instructions. Total
RNA was stored at −70◦C until use. Semiquantitative reverse
transcriptase (RT) reactions were conducted as reported
previously [26, 27]. Quantiﬁcation of mRNA was performed
using real-time RT-PCR according to the manufacturer’s
instructionsforSYBRPremixExTaq(TakaraBio,Inc.,Shiga,
Japan) using a real-time thermal cycler (Bio-Rad, Hercules,
CA,USA)asreportedpreviously[28].Resultswereexpressed
as optimal density ratios to GAPDH. Primers (Bioneer,
Daejeon, Korea) are in Table 1.
2.10. Statistical Analysis. Data (Figures 1(b)–1(d), 2(c)–2(f),
4(b)–4(e), 4(g), 5(a), 5(b),a n d5(e)) are expressed as the
mean with standard deviation (SD) as calculated from one
(n = 6) of two independent experiments. Other data are rep-
resentativeofthreediﬀerentexperimentswithsimilarresults.
For statistical comparisons, results were analyzed using
Mann-Whitney test. All P values < 0.05 were considered
statistically signiﬁcant. All statistical tests were conducted
using SPSS (SPSS Inc., Chicago, IL, USA).
3. Results and Discussion
As previously reported, BAY showed strong inhibition of
NF-κB activation. BAY blocked the production of NO,
PGE2,a n dT N F - α, well-known inﬂammatory responses
generatedbyactivatedNF-κB[29],inLPS-treatedRAW264.7
cells (Figures 1(b) and 1(d)) and peritoneal macrophages
(Figure 1(c)). It suppressed the translocation of NF-κB
subunit (p65) in a time-dependent manner (Figure 2(a)
left panel) and blocked the phosphorylation of p50 and
p65 in whole cell lysates (Figure 2(b)), without altering cell
viability up to 20μM( Figure 2(a) right panel), indicating
that it could speciﬁcally block the activation and translo-
cation pathway of NF-κBa sr e p o r t e dp r e v i o u s l y[ 30]. As
shown in Figures 2(c)–2(f),B A Y( 0t o2 0 μM) diminished
the activity of NF-κB induced by PMA, a cell permeable
PKC activator, and adaptor or signaling molecules of TLR6 Mediators of Inﬂammation
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Figure 3: Eﬀect of BAY on the activation of upstream signaling for NF-κB translocation. (a to c) RAW264.7 cells (a left panel, b, and c) or
peritoneal macrophages (a right panel) (5×106 cells/mL) were incubated with BAY (15μM) in the presence or absence of LPS (1μg/mL) for
indicated times. After preparing whole lysates, levels of phospho (p)- or total proteins of IκBα,I K K α/β, Akt, p85/PI3K, Syk, and Src were
identiﬁed by immunoprecipitation. Relative intensity (a right panel) was calculated by densitometric scanning.
(TRIF, MyD88, and TBK1), as assessed by reporter gene
assay. Furthermore, IκBα phosphorylation [31], a rep-
resentative upstream pathway for NF-κB translocation,
was also strongly suppressed in LPS-treated RAW264.7
cells (Figure 2(g) left panel) and peritoneal macrophages
(Figure 2(g) right panel), as reported previously [32], due to
its direct inhibition of IKK [33].
Unexpectedly, however, the pharmacological activity of
BAY seemed not to be limited to IKK inhibition. It clearly
suppressed IKK phosphorylation (Figure 3(a) left panel),
mediated by Akt in inﬂammatory signaling. Furthermore,
it blocked the phosphorylation of Akt in both LPS-treated
RAW264.7 cells (Figure 3(a) right panel) and peritoneal
macrophages (Figure 3(a) right panel), indicating that the
target of BAY in inﬂammatory signaling was upstream of
IKK and Akt. Since Src and Syk are representative upstream
kinases that activate PI3K, PDK1, and Akt by cascade
phosphorylation [34], we evaluated whether these enzymes
were suppressed by BAY. As shown in Figures 3(b) and
3(c), BAY did not suppress the phosphorylation of p85,
a regulatory subunit of PI3K [35], or its upstream kinases
Syk and Src, but diminished p-IKK levels at 2min. This
suggested that the target of BAY in the NF-κB inhibitory
pathway was not IKK, but a protein activated upstream of
IKK and downstream of Src and Syk. Currently, we do not
know which enzyme directly contributes to inhibition by
BAY.OneofthreePI3KisoformsorPDK1couldbetheactual
target that is regulated by BAY. We plan to conduct future
experiments to determine this.
In addition to NF-κB, AP-1 is a representative transcrip-
tion factor that is activated in inﬂammatory responses [36].
Therefore, we examined whether BAY blocked the activation
of AP-1 in LPS-treated RAW264.7 cells, by measuring the
nuclear translocated level of AP-1 components, c-Jun and c-
Fos, and using a reporter gene (luciferase) assay with DNA
construct containing an AP-1-binding promoter region. As
seen in Figures 4(a)–4(d), BAY suppressed the promoter-
binding activity of AP-1 induced by PMA and TBK1, but not
TRIF and MyD88, as assessed by luciferase activity. Similarly,
BAY also strongly suppressed nuclear translocation of c-FosMediators of Inﬂammation 7
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Figure 4:EﬀectofBAYontheactivationoftheAP-1pathway.(atod)HEK293cellscotransfectedwithAP-1-Lucconstruct(1μg/mL)andβ-
gal(asatransfectioncontrol)weretreatedwithBAY(0to20μM)inthepresenceorabsenceofPMA(100nM)orbycotransfectionwithAP-1
activation inducers (MyD88, TRIF, and TBK1). Luciferase activity was measured using a luminometer. (e) Translocated or phosphorylated
levels of AP-1 family (c-Fos and c-Jun) from the nucleus from RAW264.7 cells treated with BAY (15μM) in the presence or absence of
LPS (1μg/mL), evaluated by immunoblotting. (f) RAW264.7 cells (5 × 106 cells/mL) were incubated with BAY (15μM) in the presence or
absence of LPS (1μg/mL) for indicated times. After preparing total lysates, levels of phospho (p)- or total proteins of JNK, p38, and ERK
were identiﬁed by immunoprecipitation. (g) Levels of NO determined by the Griess assay and PGE2 by EIA from culture supernatants of
RAW264.7 cell treated with U0126 (U0), SB203580 (SB), or SP600125 (SP) in the presence or absence of LPS (1μg/mL) for 24h. ∗P<0.05
and ∗∗P<0.01 compared to the control.
and c-Jun (Figure 4(e)), indicating that it could modulate
the activation pathway required for the translocation of AP-
1. Indeed, BAY reduced important upstream events for AP-1
translocation.Thus,itdiminishedthephosphorylationlevels
of ERK at 5min and p38 at 15min although it also increased
the phosphorylation of ERK at 15 to 30min (Figure 4(f)).
Therefore, our data suggested that BAY had a negative eﬀect
on AP-1 activation pathway, managed by PKC and TBK1,
via indirectly suppressing MAPK (ERK and p38) activation
pathway. The fact that U0126 (U0), an ERK inhibitor, and
SB203580 (SB), a p38 inhibitor, blocked the production
of PGE2 and TNF-α (data not shown), but not NO
(Figure 4(g)), implies that BAY-mediated inhibition of ERK
and p38 phosphorylation did not aﬀect its NO inhibitory
action.
Recent work on inﬂammatory signaling demonstrated a
critical role for IRF-3 in releasing type I interferons such
as IFN-α and IFN-β [37], and additional inﬂammatory
responsesbythesecytokinesviaactivationoftheJAK2/STAT-
1p a t h w a y[ 38]. The activation of the JAK2/STAT-1 pathway
is important in the expression of iNOS and COX-2 and other
proinﬂammatory cytokines such as IL-1β and TNF-α [39].
BlockadeoftheIRF-3pathwaywithBX795,aTBK1inhibitor
[40], blocked the expression of iNOS and COX-2 and
suppressed the production of NO and PGE2 (Figure 5(a)).
AG490, an inhibitor of JAK2/STAT-1 pathway also elicited
strong anti-inﬂammatory responses (Figure 5(b)). There-
fore, we examined whether these pathways were also targeted
by BAY. BAY strongly suppressed the translocation of IRF3
into the nucleus (Figure 5(c)) and its phosphorylation in
the cytosol (Figure 5(d)). This indicated that the IRF-3
regulatory pathway was also directly modulated by BAY. In
agreement, BAY diminished the upregulation of luciferase
activity induced by TBK1 (Figure 5(e)), suggesting that
the TBK1-mediated inﬂammatory pathway was a BAY
target. Suppression of the JAK2/STAT-1 pathway by BAY
was determined by measuring the nuclear translocation
of phospho-STAT-1 and its upstream kinase. This also
strongly indicated involvement in BAY-mediated inhibition.
BAY strongly suppressed the phosphorylation of STAT-1 at
120min in the nucleus (Figure 5(f))a n dJ A K - 2a t0 . 2 5a n d
2min in whole cell lysates (Figure 5(g)), suggesting that the
JAK-2/STAT-1-mediated inﬂammatory responses were also
targeted by BAY.
The mechanism of broad-spectrum pharmacological
activity of BAY in various inﬂammatory signaling pathways
is not clear. The main factor of this could be derived by
its structural properties. Several compounds (e.g., celecoxib,
phenylpropanoid derivatives) with a methylphenyl group
in their backbone display anti-inﬂammatory activity by
inhibiting various enzyme targets [41, 42]. Recently, we
have also found that 8-(tosylamino)quinoline (8-TQ), with
a similar structural backbone, strongly suppresses various
inﬂammatory signaling cascades (Jung et al., submitted).
Therefore, our data suggested that a structural feature of
BAY contributed to its multiple pharmacological activities.
Since a compound, 3-(4-(tert-octyl)phenoxy)propane-1,2-
diol, with multiple inhibitory targets such as Syk, IKK, and
p38,wasfoundtodisplayhigherinvivoeﬃcacy[43],itseems
to be worth to further develop BAY derivatives. In view of
this, we are currently collaborating with several Chemists
to synthesize and develop pharmacologically stronger BAY
derivatives.
In summary, BAY exhibited broad-spectrum inhibitory
activity against inﬂammatory signaling pathways including
PI3K/Akt/IKK/NF-κB, ERK/JNK/AP-1, TBK1/IRF-3, andMediators of Inﬂammation 9
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Figure 5: Eﬀect of BAY on the activation of the IRF-3 pathway. (a left panel and b) Levels of NO by the Griess assay and PGE2 by EIA from
culture supernatants of RAW264.7 cell treated with BX795 (5μM) or AG490 (20μM) in the presence or absence of LPS (1μg/mL) for 24h.
(a right panel) Levels of COX-2 and iNOS mRNA by real-time PCR using LPS-treated RAW274.7 cells pretreated with BX795 (5μM) for
6h. (c, d, f, and g) Translocated or phosphorylated levels of IRF-3, STAT-1 or JAK2 from nucleus (c and f) or total lysates (d and g) from
RAW264.7 cells treated with BAY (15μM) in the presence or absence of LPS (1μg/mL) for indicated times, evaluated by immunoblotting.
(e) HEK293 cells cotransfected with IFN-β-promoter-1-Luc construct (1μg/mL) and β-gal (as a transfection control) were treated with BAY
in the presence or absence of TBK1 (1μg/mL). Luciferase activity was measured using a luminometer. Relative intensity (c) was calculated
by densitometric scanning. ∗P<0.05 and ∗∗P<0.01 compared to the control.
JAK-2/STAT-1. The suppressive activity of BAY was linked to
the suppression of NO, TNF-α,a n dP G E 2 release. Although
the direct target of BAY needs to be identiﬁed, our data
strongly implied that BAY inhibited the TLR4-activated
signaling cascade and the subsequentinﬂammatory response
by targeting multiple signaling enzymes and transcription
factors. Considering that inﬂammatory responses occurred
through multiple signaling pathways, and simultaneous
inhibition of these pathways contributes to maximum thera-
peutic potential, the chemical optimization of BAY could be
helpful in developing strong BAY-derived anti-inﬂammatory
drugs with multiple targets.
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